W8MD Diet | COVID-19 portal | Vitamin D | Vaccine | Keto

WikiMD is the world's largest medical encyclopedia with
312,668 pages, 4,244,543 edits & 44,197,833 views.

Free unbiased diet, health and wellness info!

Filgrastim

From WikiMD's free health, diet & wellness encyclopedia
(Redirected from Accofil)
Jump to navigation Jump to search

filgrastim (fil-GRAS-tim)A drug used under the brand names Neupogen, Zarxio, and Granix to treat neutropenia (a condition in which there is a lower-than-normal number of white blood cells) caused by some types of chemotherapy. It is also used under the brand names Neupogen and Zarxio to help prevent infection in patients with certain types of cancer, to treat severe chronic neutropenia, and to prepare the blood for the collection of certain types of blood cells. Filgrastim helps the bone marrow make more white blood cells. It is a type of colony-stimulating factor. Also called G-CSF and granulocyte colony-stimulating factor.


Information about Filgrastim

Filgrastim (fil gra' stim) is a recombinant, non-glycosylated form of the 175 amino acid protein, granulocyte colony stimulating factor (G-CSF) that induces the proliferation and maturation of neutrophils.  G-CSF is normally produced by multiple cell types including monocytes, fibroblasts, macrophages and stromal cells.  It acts on specific receptors found on granulocyte progenitors and causes an increase in circulating neutrophils.  Recombinant filgrastim has been shown to increase total neutrophil counts and to protect, in part, against severe infections in patients with neutropenia for various causes.

FDA approval information for Filgrastim

Filgrastim was approved for use in the United States in 1991, and current indications are for chemotherapy induced neutropenia, in hematopoietic cell transplantation after myeloablation and in congenital and cyclic neutropenias.  Filgrastim is also used in patients undergoing autologous peripheral blood progenitor (stem) cell collection.  Filgrastim is available as a solution in single use vials or prefilled syringes (300 and 600 mcg each) for subcutaneous or intravenous administration under the brand name Neupogen. 

Dosage and administration for Filgrastim

Dose regimens vary by indication (5 or 10 mcg/kg per day) and route of administration (intravenous or subcutaneous).

Pegylated longacting form - pegfilgrastim

A pegylated, long acting form of G-CSF (pegfilgrastim) became available in 2002 under the brand name Neulasta which can be given once weekly and has similar efficacy and safety as filgrastim.  The current formal indications for pegfilgrastim are limited to prevention of febrile neutropenia during myelosuppressive cancer chemotherapy for non-myeloid malignancies.  Pegfilgrastim is available in solution of 6 mg/0.6 mL in prefilled syringes.  The typical dose is 6 mg subcutaneously once per chemotherapy cycle.  Common side effects of filgrastim and pegfilgrastim include fever, musculoskeletal pain, rash, cough and shortness of breath.  Rare side effects include acute allergic reactions, splenic rupture and acute respiratory distress syndrome.

Sargramostim

Sargramostim (sar gra' moe stim) is a recombinant form of granulocyte-macrophage stimulating factor (GM-CSF) that stimulates the proliferation and maturation of neutrophils and macrophages.  Sargramostim is prepared in yeast (S. cerevisae) and is a 127 amino acid glycoprotein that is 98% identical to native, human GM-CSF.  Sargramostim increases the number and activity of circulating neutrophils and monocytes.  Sargramostim was approved in the United States in 1991 for use in patients with acute myelogenous leukemia after chemotherapy induced neutropenia.  Current indications also include support of patients undergoing hematopoietic cell transplantation as well as for patients undergoing autologous peripheral blood progenitor (stem) cell collection.  Sargramostim is available in liquid and lyophilized forms under the brand names Leukine and Prokine.  Sargramostim is given either intravenously or subcutaneously daily or three times weekly, the dose and regimen varying by indication.  Common side effects include fever, headache, fatigue, bone pain, nausea and weakness, but similar rates of these symptoms are reported with placebo or comparator therapies.

Hematologic Agents Eculizumab, Emapalumab, Emicizumab, Lanadelumab, Ravulizumab

Hematologic Growth Factors

  • Granulocyte-Macrophage Colony Stimulating Factors

Thrombopoietin receptor agonists and Thrombopoiesis Stimulators

Learn more about Filgrastim

Latest research - Filgrastim

PubMed
Clinical trials

External links

Wikipedia
Medicine icon
Medicine icon

This WikiMD article Filgrastim is a stub. If you are familiar with the topic Filgrastim, you can help us. Paid editors welcome!

 

Filgrastim is part of WikiMD's free ^articles!

^Filgrastim (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available